Medline Industries recalled 1,212 kits containing Tego Connectors on January 8, 2026. The recall stems from issues with silicone seals that may cause occluded fluid paths. Users may experience delays in therapy or exposure to contaminants due to this defect.
Affected lots may exhibit issues with the silicone seal on Tego Connectors included in kits. Issues include silicone seal doming and silicone seal tearing. These issues may result in an occluded fluid path identified by the inability of the user to inject or withdraw blood product with a syringe. Damaged seals may also result in delay in therapy or fluid leakage, interruption in therapy, exposure to biological contaminants or air infused into the body.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Medline Industries, LP or your healthcare provider for instructions. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recall includes the Medline Apheresis SubQport Access Kit (SKU DYNDA2705) and the Medline Central Line Insertion Kit (SKU DYNJ63347A). These products were distributed nationwide in the U.S.
Affected lots may exhibit silicone seal doming or tearing. These defects can block fluid paths, leading to the inability to inject or withdraw blood products.
There have been no reported injuries or deaths linked to this recall. However, the potential risks include delays in therapy and exposure to biological contaminants.
Stop using the recalled products immediately. Follow instructions provided by Medline Industries or your healthcare provider regarding the return process.
For assistance, contact Medline Industries at 1-800-633-5463 or visit their website for more information.
Get instant alerts for recalls that affect you. Free forever.
AvKARE recalled Amantadine HCl capsules on February 13, 2026, due to failed dissolution specifications. The recall affects the 100 mg capsules, which may not dissolve properly. Consumers should stop using this product and contact their healthcare provider immediately.
Slate Run Pharmaceuticals recalled Eptifibatide Injection on February 12, 2026. The recall affects all lots of the 75 mg/100 mL vial due to incorrect dosing information. Healthcare providers and consumers must stop using the product immediately.
LEO Pharma Inc. recalled 11,407 units of Adbry injection on February 10, 2026. The recall stems from a lack of assurance of sterility due to particulate matter identified as wool fiber. Consumers should stop using the product immediately and contact their healthcare provider for guidance.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Hitachi Ltd. recalled one unit of its Proton Beam Therapy System on February 6, 2026 due to a software anomaly. The issue may result in positional discrepancies during patient treatment. The recall affects distribution in Texas and Washington D.C.
Hitachi recalled its Proton Beam Therapy System on February 6, 2026, due to a software anomaly that may result in positional discrepancies. The recall affects one unit distributed in Texas and Washington D.C. Healthcare providers and patients must stop using the device immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.